

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7564310

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	GILEAD BIOLOGICS, INC.	09/27/2022
RECEIVING PARTY DATA		
Name:	GILEAD SCIENCES, INC.	
Street Address:	333 LAKESIDE DRIVE	
City:	FOSTER CITY	
State/Country:	CALIFORNIA	
Postal Code:	94404	
PROPERTY NUMBERS Total: 7		
Property Type	Number	
Patent Number:	8377443	
Patent Number:	8501916	
Patent Number:	9120863	
Patent Number:	9260532	
Patent Number:	9550836	
Patent Number:	10800857	
Application Number:	17017491	
CORRESPONDENCE DATA		
Fax Number:	(650)522-5575	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6505743000	
Email:	erika.wong5@gilead.com	
Correspondent Name:	GILEAD SCIENCES, INC.	
Address Line 1:	333 LAKESIDE DRIVE	
Address Line 4:	FOSTER CITY, CALIFORNIA 94404	
ATTORNEY DOCKET NUMBER:	A17 AND A21	
NAME OF SUBMITTER:	JENNIFER L. WAHLSTEN	
SIGNATURE:	/Jennifer L. Wahlsten, Reg. No. 46,226/	
DATE SIGNED:	09/28/2022	

Total Attachments: 14

source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page1.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page2.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page3.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page4.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page5.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page6.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page7.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page8.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page9.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page10.tif
source=Confirmatory Assignment for A17 and A21 (Gilead Biologics to Gilead Sciences) 2022-09-27#page11.tif
source=Certificate of Ownership _ Merger - Gilead Biologics Inc#page1.tif
source=Certificate of Ownership _ Merger - Gilead Biologics Inc#page2.tif
source=Certificate of Ownership _ Merger - Gilead Biologics Inc#page3.tif

CONFIRMATORY ASSIGNMENT – WORLDWIDE

WHEREAS Gilead Biologics, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having an address at 333 Lakeside Drive, Foster City, California 94404, (hereinafter "Assignor") is the owner of the Patents or Patent Applications, both U.S. and all foreign countries, listed in Exhibit A, as well as the inventions set forth therein;

WHEREAS Gilead Sciences, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having an address at 333 Lakeside Drive, Foster City, California 94404, (hereinafter referred to singly and collectively as "Assignee") is desirous of acquiring the full right, title and interest in and to said inventions and in and to said Patents or Patent Applications for U.S. and all foreign countries and especially the countries listed in Exhibit A;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to Assignee the entire right, title and interest in and to said inventions for U.S. and all foreign countries, and in and to said Patents and Patent Applications listed in Exhibit A, including any and all priority applications, divisional, continuation, continuation-in-part, reissues or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made; the Commissioner or Director of U.S. and each foreign Patent Office is hereby authorized to transfer Assignee's interest to said Patents or Patent Applications to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the Assignor, Assignor hereby undertakes to execute and deliver to Assignee upon request all lawful documents which may be requested by Assignee, and to furnish Assignee with all facts relating to said invention as may be requested.

Executed this 27 day of September, 2022.


Signature

Jennifer L. Wahlsten
Name

Associate General Counsel, Intellectual Property
Title
for
GILEAD BIOLOGICS, INC.
333 Lakeside Drive
Foster City, California 94404
(ASSIGNOR)

ACCEPTED BY:

Executed this 27 day of September, 2022.


Signature

Jennifer L. Wahlsten
Name

Associate General Counsel, Intellectual Property
Title
for
GILEAD SCIENCES, INC.
333 Lakeside Drive
Foster City, California 94404
(ASSIGNEE)

EXHIBIT A

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A17-AP	AP	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-AP-D	AP	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-AT	AT	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-AU	AU	Granted	2011293125	2011293125	21 May 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-AU-D	AU	Granted	2015201367	2015201367	30 Mar 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-AU-D2	AU	Abandoned	2017201656			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-BE	BE	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-BN-SG	BN	Abandoned	201301134-1	RE/R/2016/0038	29 Aug 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-BR	BR	Abandoned	BR1120130045795	1120130045795	12 Mar 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-BW	BW	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-BW-D	BW	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CA	CA	Granted	2808418	2808418	05 Feb 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CH	CH	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CL	CL	Abandoned	535-2013	55.137	18 Aug 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CN	CN	Granted	201180641422.8	ZL201180641422.8	21 Jan 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CN-D	CN	Granted	201410816632.5	ZL201410816632.5	26 Nov 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CO	CO	Abandoned	13-036.730	6015	15 Jan 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CR	CR	Abandoned	2013-0132			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-CZ	CZ	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-DE	DE	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-EA	EA	Abandoned	201390146	031729	28 Feb 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A17-EC	EC	Abandoned	SP-13-12525			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-EG	EG	Abandoned	PCT/94/2013			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-EP	EP	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ES	ES	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-FR	FR	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-GB	GB	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-GH	GH	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-GH-D	GH	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-GM	GM	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-GM-D	GM	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-GR	GR	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-HK-CND	HK	Granted	15109390.0	HK1208688	18 Dec 2020	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-HK-EP	HK	Granted	13107968.8	1180603	19 Jun 2020	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ID	ID	Abandoned	W00201301191	W00201301191	30 Sep 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ID-D	ID	Abandoned	P00201504797			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-IE	IE	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-IL	IL	Abandoned	224614	224614	01 Mar 2018	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-IL-D	IL	Abandoned	255300			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-IN	IN	Granted	1565/DELNP/2013	308368	28 Feb 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-IN-D	IN	Abandoned	201818026034			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-IT	IT	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-JP	JP	Granted	2013-526186	5878538	05 Feb 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-JP-D	JP	Granted	2015-208653	6198797	01 Sep 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A17-JP-D2	JP	Granted	2017-159712	6435381	16 Nov 2018	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-KE	KE	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-KE-D	KE	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-KR	KR	Granted	10-2013-7007599	10-1518144	29 Apr 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-KR-D	KR	Granted	10-2014-7035325	10-1827048	01 Feb 2018	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-KR-D2	KR	Granted	10-2017-7006624	10-1930179	11 Dec 2018	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-KR-D3	KR	Granted	10-2018-7002896	10-1881724	18 Jul 2018	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-LR	LR	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-LR-D	LR	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-LS	LS	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-LS-D	LS	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MA	MA	Abandoned	35741	34527	02 Sep 2013	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MO-CN	MO	Granted	J/001729	J/001729	13 Jul 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MW	MW	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MW-D	MW	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MX	MX	Abandoned	MX/a/2013/002323	342413	28 Sep 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MX-D	MX	Abandoned	MX/a/2016/004652			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MZ	MZ	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-MZ-D	MZ	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NA	NA	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NA-D	NA	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NL	NL	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NO	NO	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A17-NZ	NZ	Abandoned	606880	606880	01 May 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NZ-D	NZ	Abandoned	701444	701444	27 Sep 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NZ-D2	NZ	Abandoned	720143			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-NZ-D3	NZ	Abandoned	737487			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-OA	OA	Abandoned	1201300072			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-PE	PE	Abandoned	344.2013	8416	22 Aug 2017	ANTI-METALLOPROTEINASE MATRIX 9
A17-PH	PH	Abandoned	1-2013-500347	1-2013-500347	09 May 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-PH-D	PH	Abandoned	1-2016-501691			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-PL	PL	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-PT	PT	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SD	SD	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SD-D	SD	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SE	SE	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SG	SG	Abandoned	201301134-1	188224	27 Aug 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SG-D	SG	Abandoned	16201506703V			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SI	SI	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SK	SK	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SL	SL	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SL-D	SL	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SV	SV	Abandoned	E-4410-2013			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SZ	SZ	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-SZ-D	SZ	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-TH	TH	Abandoned	1361000976			ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A17-TK	TK	Granted	11820759.6	2608809	22 May 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-TZ	TZ	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-TZ-D	TZ	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-UA	UA	Abandoned	a201302088	109908	26 Oct 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-UG	UG	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-UG-D	UG	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-I	US	Granted	13/219523	8377443	19 Feb 2013	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-D	US	Granted	13/619318	8301916	08 Aug 2013	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-D2	US	Granted	13/935370	9120863	01 Sep 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-D3	US	Abandoned	14/839303			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-D3C	US	Abandoned	15/695765			NUCLEIC ACIDS ENCODING ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-DC	US	Granted	13/935352	9260532	16 Feb 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-DCD	US	Abandoned	14/992678			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-US-P	US	Expired	61/377886			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-VN	VN	Abandoned	1-2013-00903			MATRIX METALLOPROTEINASE 9 BINDING PROTEINS, NUCLEIC ACIDS, METHODS, AND COMPOSITIONS
A17-WO-PF	WO	Expired	US2011/049448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ZA	ZA	Abandoned	2013/01338	2013/01338	27 Jul 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ZA-D	ZA	Abandoned	2015/07081	2015/07081	22 Feb 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ZM	ZM	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ZM-D	ZM	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ZW	ZW	Abandoned	AP/P/2013/006743	0003948	21 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A17-ZW-D	ZW	Abandoned	AP/P/2016/009448			ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A21-AE	AE	Abandoned	913/2014			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-AP	AP	Abandoned	AP/P/2014/007907			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-AU	AU	Abandoned	2012318302	2012318302	01 Dec 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-AU-D	AU	Abandoned	2015242967	2015242967	07 Dec 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-AU-D2	AU	Abandoned	2017216508	2017216508	20 Jun 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-AU-D3	AU	Abandoned	2017261626			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-BF	BF	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-BH	BH	Abandoned	BP116/2014			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-BJ	BJ	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-BR	BR	Abandoned	BR112014021477-8			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CA	CA	Abandoned	2865530	2865530	19 Feb 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CF	CF	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CG	CG	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CI	CI	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CL	CL	Abandoned	2282-2014			ANTIBODIES AGAINST METALLOPROTEINASE OF MATRIX 9 (MMP9 GELATINASE B); PHARMACEUTICAL COMPOSITION THAT CONTAINS IT; AND ITS USES.
A21-CL-D	CL	Abandoned	201602014			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CM	CM	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CN	CN	Abandoned	201280072749.6	ZL201280072749.6	04 Mar 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-CO	CO	Abandoned	14190943	6391	20 Oct 2015	MATRIX METALLOPROTEINASE ANTIBODY 9
A21-CR	CR	Abandoned	2014-0443			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-DE	DE	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-EA	EA	Abandoned	201491575			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-EC	EC	Abandoned	EEPI-2014-20304			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-EG	EG	Abandoned	PC11372/2014			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-EP	EP	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-ES	ES	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-FR	FR	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-GA	GA	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-GB	GB	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A21-GN	GN	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-GQ	GQ	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-GW	GW	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-HK-CN	HK	Abandoned	15108571.3			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-HK-EP	HK	Granted	15105849.5	1205153	22 May 2020	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-ID	ID	Abandoned	P00201405678			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-IE	IE	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-IL	IL	Abandoned	234304			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-IN	IN	Abandoned	8011/DELNP/2014			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-IT	IT	Granted	12708473.9	2820048	17 Apr 2019	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-JP	JP	Abandoned	2014-539272	6067756	06 Jan 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-JP-D	JP	Abandoned	2016-49456			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-JP-D2	JP	Abandoned	2018-16563			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-KM	KM	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-KR	KR	Abandoned	10-2014-7026786			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-MA	MA	Abandoned	37361	33970	01 Dec 2014	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-MD	MD	Abandoned	a20140107			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-ML	ML	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-MR	MR	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-MX	MX	Abandoned	MX/a/2014/010449			MATRIX METALLOPROTEINASE 9
A21-MY	MY	Abandoned	P12014002521			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-NE	NE	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-NZ	NZ	Abandoned	629888	629888	25 May 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-NZ-DIV	NZ	Abandoned	726487			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-OA	OA	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-OM	OM	Abandoned	OMP/2014/00179			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-PE	PE	Abandoned	1339.14			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-PH	PH	Abandoned	1-2014-501931			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-QA	QA	Abandoned	QA/201408/00307			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-SG	SG	Abandoned	11201405305P	11201405305P	02 Feb 2017	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-SG-DIV	SG	Abandoned	10201700568R			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-SN	SN	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-SV	SV	Abandoned	E-4798-2014			ANTIBODIES TO MATRIX METALLOPROTEINASE 9

Gilead Ref. No.	Country Code	Current Status	Filing Number	Grant Number	Grant Date	Title
A21-TD	TD	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-TG	TG	Abandoned	1201400386	17085	29 Jun 2015	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-TH	TH	Abandoned	1401605043			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-UA	UA	Abandoned	a201410545			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-US-FUS	US	Granted	14/382301	9550836	24 Jan 2017	METHOD OF DETECTING HUMAN MATRIX METALLOPROTEINASE 9 USING ANTIBODIES
A21-US-FUSD	US	Abandoned	15/376232			METHOD OF DETECTING HUMAN MATRIX METALLOPROTEINASE 9 USING ANTIBODIES
A21-US-FUSDC	US	Granted	16/245169	10809857	13 Oct 2020	ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-US-FUSDC2	US	Published	17/017491			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-VN	VN	Abandoned	1-2014-03177			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-WO	WO	Expired	US2012/027160			ANTIBODIES TO MATRIX METALLOPROTEINASE 9
A21-ZA	ZA	Abandoned	2014/06319	2014/06319	24 Feb 2016	ANTIBODIES TO MATRIX METALLOPROTEINASE 9

CALIFORNIA ACKNOWLEDGMENT

CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California

County of San Mateo

On 09/27/2022

Date


before me, Angelica Buena Villanueva, Notary Public

Here Insert Name and Title of the Officer

personally appeared Jennifer Lynn Wahlsten

Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature

[Handwritten Signature]

Signature of Notary Public

Place Notary Seal and/or Stamp Above

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

GILEAD BIOLOGICS, INC.

WITH AND INTO

GILEAD SCIENCES, INC.

Gilead Sciences, Inc. (the "**Company**"), a corporation incorporated on the 22nd day of June, 1987, pursuant to the provisions of the General Corporation Law of the State of Delaware (the "**DGCL**"),

DOES HEREBY CERTIFY pursuant to Section 253 of the DGCL, that the Company owns all of the capital stock of Gilead Biologics, Inc., ("**Gilead Biologics**"), a corporation incorporated on the 21st day of February, 2007, pursuant to the provisions of the DGCL, and that the Company, by a resolution of its Board of Directors duly adopted at a meeting held on July 23, 2015 and filed with the minutes of the Board of Directors, determined to merge into itself Gilead Biologics, which merger shall be effective as of 11:59 pm EST on December 31, 2015, and which resolution is in the following words to wit:

WHEREAS, the Company lawfully owns all of the outstanding stock of Gilead Biologics, Inc. ("**Gilead Biologics**"), a corporation organized and existing under the laws of Delaware;

WHEREAS, the Company desires to merge into itself Gilead Biologics, and to be possessed of all the estate, property, rights, privileges and franchises of Gilead Biologics; and

WHEREAS, after due and careful consideration, the Board deems it advisable and in the best interests of the Company to merge into itself Gilead Biologics, and to be possessed of all the estate, property, rights, privileges and franchises of Gilead Biologics.

NOW, THEREFORE, BE IT RESOLVED, that, pursuant to Section 253 of the General Corporation Law of Delaware, the Company merge into itself Gilead Biologics and assume all of Gilead Biologics' liabilities and obligations (the "**Gilead Biologics Merger**"), with the Company continuing as the surviving corporation in the Gilead Biologics Merger (the "**Gilead Biologics Surviving Corporation**");

RESOLVED FURTHER, that the Gilead Biologics Merger shall be effective as of the date and time that any officer authorized pursuant to these resolutions to execute and file the Gilead Biologics Certificate deems appropriate (the "**Gilead Biologics Effective Time**");

RESOLVED FURTHER, that the certificate of incorporation and bylaws of the Company as in effect at the Gilead Biologics Effective Time shall continue in full force and effect as the certificate of incorporation and bylaws of the Gilead Biologics Surviving Corporation;

RESOLVED FURTHER, that at the Gilead Biologics Effective Time, the directors of the Company immediately prior to the Gilead Biologics Effective Time shall be the directors of the Gilead Biologics Surviving Corporation, each such director to hold office, subject to the applicable provisions of the certificate of incorporation and bylaws of the Gilead Biologics Surviving Corporation, until his or her respective successor shall be duly elected or appointed and qualified;

RESOLVED FURTHER, that at the Gilead Biologics Effective Time, the officers of the Company immediately prior to the Gilead Biologics Effective Time shall be the officers of the Gilead Biologics Surviving Corporation, subject to the applicable provisions of the certificate of incorporation and bylaws of the Gilead Biologics Surviving Corporation, until their respective successors shall be duly elected or appointed and qualified;

RESOLVED FURTHER, that at the Gilead Biologics Effective Time, all of the shares of the capital stock of Gilead Biologics issued and outstanding immediately prior to the Gilead Biologics Effective Time and all rights in respect thereof shall, by virtue of the Gilead Biologics Merger and without any action on the part of the Company, forthwith cease to be outstanding and be canceled;

RESOLVED FURTHER, that each officer of the Company be, and each hereby is, authorized to make and execute a Certificate of Ownership and Merger (the "***Gilead Biologics Certificate***") and to file such Gilead Biologics Certificate with the Secretary of State of the State of Delaware and a certified copy of the Gilead Biologics Certificate in the office of the Recorder of Deeds of New Castle County, and to make and effectuate such other documentation as may be necessary to effectuate the Gilead Biologics Merger, and to take all such action, whether within or without the State of Delaware, that may be in any way necessary or proper to effect the Gilead Biologics Merger;


RESOLVED FURTHER, that the appropriate officers of the Company be, and each of them hereby is, authorized and directed, for and on behalf of the Company, to take any and all steps and do any and all things which they may deem necessary or advisable in order to effectuate the intent and purposes of each and all of the foregoing resolutions; and

RESOLVED FURTHER, that all actions and deeds heretofore taken by any officer of the Company in connection with the transactions contemplated by the Gilead Biologics Certificate are hereby approved, ratified and confirmed in all respects.

[Signature page follows.]

IN WITNESS WHEREOF, the Company has caused this certificate to be signed by an authorized officer on this ____ day of December, 2015.

GILEAD SCIENCES, INC.

By: 
Name: Brett Fletcher
Title: Secretary

*[Signature Page to Certificate of Ownership and Merger --
Gilead Sciences, Inc. and Gilead Biologics, Inc.]*